Early Orthopedic Surgery in Intermediate-low and low-risk Pulmonary Embolism Patients: A Multi-centre study to determine the safety of Surgical Intervention
Keywords:
Safety, Orthopedic Surgery, Pulmonary Embolism, RiskAbstract
Background: Globally, the incidence and prevalence of venous thromboembolism (VTE), which encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE), is on the rise. Between twenty and thirty percent of all PE occurrences have other causes, such as recent immobilization, severe surgery, and trauma. Preoperative pulmonary embolism (PE) is a common condition among individuals who have had a hip fracture. Objective: To explore whether early orthopedic surgery is safe for individuals who have low-risk or intermediate-low-risk pulmonary emboli. Methodology: The current study was conducted at the Orthopedic Department, Bacha Khan Medical Complex and Medical Teaching Institute (MTI), Mardan Medical Complex, Mardan from December 2018 to November 2020. The enrolled individuals in the current study were divided into PE group and non-PE group. The PE group comprises individuals who received a verified diagnosis of PE before undergoing surgery, whereas non-PE-group consists of those who did not get an official diagnosis of PE during their hospital stay. For comparison of categorical data, the chi-square or Fisher's exact test were employed whereas for continuous data the Mann-Whitney U-test was used. Approval of the study was taken from ethical committee of MTI Mardan Medical Complex, Mardan. Results: Totally, 160 participants with hip fracture were enrolled in our study. All were diagnosed with pulmonary CT angiography. During the postoperative phase, 18 patients (11.25%) were diagnosed with PE. As a result, 92 participants (57.5%) were placed in the PE-group, whereas in non-PE-group, 52 patients (32.5%) were assigned. The baseline features of the PE and non-PE-groups and postoperative PE-group did not vary statistically. Within the PE-group, deep vein thrombosis (DVT) was identified in 39.1% of the individuals. Conclusion: It was concluded from the current study that prompt surgical intervention may be clinically viable and reasonably safe for individuals with acute pulmonary embolism and hip fractures.References
Huang W, Goldberg RJ, Anderson FA, Kiefe CI, Spencer FA.Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009). Am J Med. 2014; 127:829-39.-5
Huang D, Chan PH, She HL, Wong CK, Ho CW, Cheng YY, et al. Secular trends and etiologies of venous thromboembolism in Chinese from 2004 to 2016. Thromb Res. 2018; 166:80-5.
Hong J, Lee JH, Yhim HY, Choi WI, Bang SM, Lee H, Oh D. Incidence of venous thromboembolism in Korea from 2009 to 2013. PLoS One. 2018; 13:-0191897.
Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: Chest guideline and expert panel report. Chest. 2016; 149:315-52.
Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17:-452-e466.
Wendelboe AM, Raskob GE. Global burden of thrombosis: Epidemiologic aspects. Circ Res. 2016; 118:1340-7
Gjonbrataj E, Kim JN, Gjonbrataj J, Jung HI, Kim HJ, Choi WI. Risk factors associated with provoked pulmonary embolism. Korean J Intern Med. 2017;32:95-101.
Serhal M, Barnes GD. Venous thromboembolism: A clinician update. Vasc Med 2019; 24:122-31.
Roberts TS, Nelson C, Barnes CL, Ferris EJ, Holder JC, Boone DW.The preoperative prevalence and postoperative incidence of thromboembolism in patients with hip fractures treated with dextran prophylaxis. Clin Orthop Relat Res. 1990;(255):198-203.
Rosencher N, Vielpeau C, Emmerich J, Fagnani F, Samama CM. Venous thromboembolism and mortality after hip fracture surgery: the ESCORTE study. J Thromb Haemost. 2005; 3:2006-14.
Shin WC, Woo SH, Lee SJ, Lee JS, Kim C, Suh KT.Preoperative prevalence of and risk factors for venous thromboembolism in patients with a hip fracture: An indirect multidetector CT venography study. J Bone Joint Surg Am. 2016; 98:2089-95.
Jaffer AK, Brotman DJ, Chukwumerije N. When patients on warfarin need surgery. Cleve Clin J Med. 2003; 70:973-84.
O'Donnell M, Kearon C. Perioperative management of oral anticoagulation. Cardiol Clin. 2008; 26:299-309, viii.
Simunovic N, Devereaux PJ, Sprague S, Guyatt GH, Schemitsch E, DeBeer J, et al. Effect of early surgery after hip fracture on mortality and complications: systematic review and meta-analysis. CMAJ. 2010; 182:1609-16.
Orosz GM, Magaziner J, Hannan EL, Morrison RS, Koval K, Gilbert M, et al. Association of timing of surgery for hip fracture and patient outcomes. JAMA. 2004; 291:1738-43.
Jiménez D, Aujesky D, Moores L, Gómez V, Lobo JL, Uresandi F, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010; 170:13839.
Konstantinides S, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014; 35:3033-69, 3069a-3069k.
Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS,Perioperative management of antithrombotic therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012; 141:e326S-e50S.
Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D). J Clin Oncol. 2018; 36:2017-23
Lee JH, Hyun DG, Choi CM, Lee JC, Kim WS, Oh YM, et al. A retrospective study on efficacy and safety of rivaroxaban and dalteparin for long-term treatment of venous thromboembolism in patients with lung cancer. Respiration. 2019; 98:203-11.
Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010; 8:202-4.
Büller HR, Prins MH. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366:1287-97.
Eriksson BI, Lassen MR. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2003; 163:1337-42.
Westrich GH, Rana AJ, Terry MA, Taveras NA, Kapoor K, Helfet DL. Thromboembolic disease prophylaxis in patients with hip fracture: a multimodal approach. J Orthop Trauma. 2005; 19:234-40.
Zahn HR, Skinner JA, Porteous MJ. The preoperative prevalence of deep vein thrombosis in patients with femoral neck fractures and delayed operation. Injury. 1999; 30:605-7.
Smith EB, Parvizi J, Purtill JJ. Delayed surgery for patients with femur and hip fractures-risk of deep venous thrombosis. J Trauma. 2011; 70:E113-6.
Lu Y, Ma B, Guo R, Wang Y, Zhang J, Wu Y, Pang G, et al. Deep vein thrombosis in trauma: a prospective study of lower limb orthopedic trauma patients in Tianjin Hospital, China. Int Angiol. 2007; 26:165-70.
Cho YH, Byun YS, Jeong DG, Han IH, Park YB. Preoperative incidence of deep vein thrombosis after hip fractures in Korean. Clin Orthop Surg. 2015; 7:298-302.
Grant PJ, Brotman DJ, Jaffer AK. Perioperativ anticoagulant management. Med Clin North Am. 2009; 93:1105-21
McBane RD, Wysokinski WE, Daniels PR, et al. Periprocedural anticoagulation management of patients with venous thromboembolism. Arterioscler Thromb Vasc Biol. 2010;30:442-8.
Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012; 120:2954-62.
Stein PD, Kayali F, Olson RE. Twenty-one-year trends in the use of inferior vena cava filters. Arch Intern Med. 2004; 164:1541-5.
Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest 2002; 122:963-7.
Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du risqué d'embolie pulmonaire par interruption cave study group. N Engl J Med. 1998; 338:409-15.
Sarosiek S, Crowther M, Sloan JM. Indications, complications, and management of inferior vena cava filters: the experience in 952 patients at an academic hospital with a level I trauma center. JAMA Intern Med. 2013; 173:513-7.
Bérczi V, Bottomley JR, Thomas SM, Taneja S, Gaines PA, Cleveland TJ. Long-term retrievability of IVC filters: should we abandon permanent devices? Cardiovasc Intervent Radiol. 2007; 30:820-7.
Kim H, Han Y, Ko GY, Jeong MJ, Choi K, Cho YP, et al. Clinical outcomes of a preoperative inferior vena cava filter in acute venous thromboembolism patients undergoing abdominal pelvic cancer or orthopedic surgery. Vasc Specialist Int. 2018; 34:103-8
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Pakistan Journal of Chest Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
